Use our Plotter to visualize the concentration of your GLP-1 Receptor Agonist over time. This tool works as a dose calculator to help you estimate the levels of the drug in your system at any time for varying doses and timing.
NOTE: Everyone is different, and physiology can differ vastly between different people. We aim to make our calculator as accurate as possible based on publicly available data. However, the half-lives of these compounds are estimates and will differ between individuals, so caution should be advised. Use at your own risk.
Turn Your Data Into Action
Now get access to GLP-1 medications and professional guidance on optimizing your treatment.
Find a Provider*Ad
Notes:
Semaglutide
- Semaglutide is sold under the brand names Ozempic, Wegovy and Rybelsus.
- The Semaglutide half-life is estimated to be around seven days (source 1, source 2) for both injectable and oral forms.
- The absolute bioavailability of Semaglutide injections is 89% (source).
- The estimated bioavailability of Semaglutide following oral administration is approximately 1% (source).
- The recommended dosage for Semaglutide is as follows:
- 0.25 mg once weekly for the first 4 weeks
- 0.5 mg once weekly for at least 4 weeks
- 1 mg once weekly for at least 4 weeks, but only if additional glycemic control is needed
- 2mg once weekly if additional control is needed
- Semaglutide injections should be dosed subcutaneously.
Tirzepatide
- Tirzepatide is sold under the brand name Mounjaro.
- The Tirzepatide half-life is estimated to be around five days (source).
- The mean absolute bioavailability of Tirzepatide following subcutaneous administration is 80% (source).
- The recommended dosage for Tirzepatide is as follows:
- 2.5 mg once weekly for the first 4 weeks
- 5 mg once weekly for at least 4 weeks
- If additional glycemic control is needed, then the dosage can be increased by 2.5 mg after at least 4 weeks on the current dose
- The maximum dose is 15mg once weekly
- Tirzepatide should be dosed subcutaneously.
References:
- Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
- Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
- The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying